About Pudee

Reliability, Responsibility and Rapidity

Founded in 2007, focus on the synthesis of small molecule compounds and the extraction of some natural compounds. We develop, produce and sell high-quality advanced intermediates and some APIs with competitive prices.
Get Appointment

Contact Info

  • Building 2, Handa Science and Technology Park
    No. 8 Pioneer Road
    High-tech Zone. Suzhou.
  • 86 512 6803 2792
    86 512 6803 2791
  • willdyhan@pudeepharm.com
    sales@pudeepharm.com

Product List

Ledipasvir
Ledipasvir | 1256388-51-8
" Ledipasvir is a drug for the treatment of hepatitis C. it is an inhibitor of the hepatitis C virus NS5A protein. It was developed by Gilead Scienc……
Edoxaban intermediate B
Edoxaban intermediate B | 720720-96-7
 Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and approved in July 2011 in Japan……
Edoxaban intermediate C
Edoxaban intermediate C | 1243308-37-3
Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and approved in July 2011 in Japan ……
Edoxaban
Edoxaban | 912273-65-5
"  Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and approved in July 2011 in Jap……
Edoxaban intermediate A1
Edoxaban intermediate A1 | 1353893-22-7
" Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and approved in July 2011 in Japa……
Edoxaban intermediate A2
Edoxaban intermediate A2 | 1210348-34-7
" Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and approved in July 2011 in Japa……
Edoxaban intermediate As
Edoxaban intermediate As | 365998-36-3
" Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and approved in July 2011 in Japa……
Ixazomib,1072833-77-2
Ixazomib,1072833-77-2 | 1072833-77-2
Suzhou Pudee is a small and below-the-radar company that has been engaged in the research and development of advanced single molecules for nearly tw……
Ibrutinib
Ibrutinib | 936563-96-1
" Ibrutinib is an anticancer drug targeting B-cell malignancies. It was approved by the US FDA on November 13, 2013 for the treatment of mantle cell……